-
公开(公告)号：US20170260274A1
公开(公告)日：2017-09-14
申请号：US15509018
申请日：2015-09-07
申请人： Michaela Arndt , Jürgen Krauss , Stefan Kiesgen
发明人： Michaela Arndt , Jürgen Krauss , Stefan Kiesgen
CPC分类号： C07K16/2863 , A61K38/465 , A61K47/65 , A61K47/6889 , A61K2039/505 , A61K2039/572 , C07K7/08 , C07K14/08 , C07K16/30 , C07K2317/24 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2319/10 , C07K2319/21 , C07K2319/33 , C07K2319/41 , C12N7/00 , C12N9/22 , C12N2770/24122 , C12N2770/24132 , C12Y301/27 , Y02A50/386
摘要： Described is a construct comprising (a) a targeting moiety; (b) a fusogenic moiety consisting one or more fusogenic sequence(s) derived from dengue virus glycoprotein E comprising the sequence DRGWGNGCGLFGKGGI (SEQ ID NO:1) or a sequence which shows 1 to 8 substitutions, deletions, or insertions in comparison to SEQ ID NO:1; and (c) a molecule which is to be delivered into the cytoplasm of a cell. Moreover, described is a pharmaceutical composition comprising the construct according to the invention and optionally a pharmaceutical acceptable carrier. Further, described is a kit comprising one or more fusogenic sequence(s) derived from dengue virus glycoprotein E comprising the sequence as shown in SEQ ID NO:1 or a sequence which shows 1 to 8 substitutions, deletions, or insertions in comparison to SEQ ID NO:1. Further, described is the use of one or more fusogenic sequence(s) derived from dengue virus glycoprotein E for use in delivery of a therapeutic moiety, a detectable moiety, a nucleic acid molecule, preferably an siRNA, a carrier molecule, preferably a nanoparticle, a liposome and a viral vector into the cytoplasm of a cell.
-
公开(公告)号：US20100216772A1
公开(公告)日：2010-08-26
申请号：US11568500
申请日：2004-10-05
申请人： Stefano Pegoraro , Martin Lang , Juliane Feurle , Jürgen Krauss
发明人： Stefano Pegoraro , Martin Lang , Juliane Feurle , Jürgen Krauss
IPC分类号： A61K31/5513 , A61P17/06 , A61P17/14 , A61P37/06 , C07D221/12 , A61K31/473 , C07D401/04 , C07D413/10 , A61K31/5377 , C07D223/18
CPC分类号： C07D221/12 , C07D233/18 , C07D401/04 , C07D401/14 , C07D405/04 , C07D405/06 , C07D405/14 , C07D409/04 , C07D409/12 , C07D409/14
摘要： The present invention relates to compounds of the general formula (IV) and (II) and salts and physiologically functional derivatives thereof, wherein X is C—R8 or N; and Z is independently one of the following groups:
摘要翻译： 本发明涉及通式（IV）和（II）的化合物及其盐和生理功能衍生物，其中X为C-R8或N; Z独立地为以下组之一：
-
公开(公告)号：US08889137B2
公开(公告)日：2014-11-18
申请号：US13499429
申请日：2010-10-01
申请人： Michael Roggendorf , Anna-Maria Eis-Hübinger , Jürgen Krauss , Karl Eduard Schneweis , Michaela Arndt , Adalbert Krawczyk , Evelyn Exner , Martin P. Däumer , Edelgard Schneweis
发明人： Michael Roggendorf , Anna-Maria Eis-Hübinger , Jürgen Krauss , Karl Eduard Schneweis , Michaela Arndt , Adalbert Krawczyk , Evelyn Exner , Martin P. Däumer
IPC分类号： A61K39/245 , C07K16/08 , A61K39/00
CPC分类号： C07K16/087 , A61K39/00 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
摘要： The invention relates to an anti-HSV antibody as defined in the claims, a pharmaceutical composition comprising of an effective amount of the said antibody, an expression vector comprising of a nucleotide sequence which encodes the said antibody, a host cell comprising of the said nucleotide sequence, a hybridoma cell capable of producing the said antibody and the use of the said antibody as a drug, in particular to use for the manufacture of a drug for the prophylactical or therapeutical treatment of HSV-associated diseases in a subject; as defined in the claims.
摘要翻译： 本发明涉及权利要求中定义的抗HSV抗体，包含有效量的所述抗体的药物组合物，包含编码所述抗体的核苷酸序列的表达载体，包含所述核苷酸的宿主细胞 序列，能够产生所述抗体的杂交瘤细胞和所述抗体作为药物的用途，特别是用于制备用于预防或治疗性治疗受试者中HSV相关疾病的药物; 如权利要求中所限定。
-
公开(公告)号：US20130058952A1
公开(公告)日：2013-03-07
申请号：US13499429
申请日：2010-10-01
申请人： Michael Roggendorf , Anna-Maria Eis-Hübinger , Jürgen Krauss , Karl Eduard Schneweis , Edelgard Schneweis , Michaela Arndt , Adalbert Krawczyk , Evelyn Exner , Martin P. Däumer
发明人： Michael Roggendorf , Anna-Maria Eis-Hübinger , Jürgen Krauss , Karl Eduard Schneweis , Edelgard Schneweis , Michaela Arndt , Adalbert Krawczyk , Evelyn Exner , Martin P. Däumer
CPC分类号： C07K16/087 , A61K39/00 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
摘要： The invention relates to an anti-HSV antibody as defined in the claims, a pharmaceutical composition comprising of an effective amount of the said antibody, an expression vector comprising of a nucleotide sequence which encodes the said antibody, a host cell comprising of the said nucleotide sequence, a hybridoma cell capable of producing the said antibody and the use of the said antibody as a drug, in particular to use for the manufacture of a drug for the prophylactical or therapeutical treatment of HSV-associated diseases in a subject; as defined in the claims.
-
-
-
搜索结果
4 条记录 (耗时 0.017 秒)
